

DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

October 21, 2020
MO HealthNet

Join WebEx Meeting

Meeting number (access code): 133 677 4310

Join from a video system or application

Dial [1336774310@stateofmo.webex.com](tel:1336774310)

You can also dial 173.243.2.68 and enter your meeting number.

Tap to join from a mobile device (attendees only)

[+1-650-479-3207,1336774310##](tel:+16504793207,1336774310) Call-in toll number (US/Canada)

[*For Meeting Documents Click Here*](#)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
10:35 – 10:45	Old Business Implementation Schedule Criteria for previously approved Clinical Edits, Step Therapies and PA's	Josh Moore
10:45 – 11:00	New Business Proposed Actions New Drug/Product Review (See website and attached summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Josh Moore
11:00 – 11:45	Clinical/Fiscal Edits <u>Existing Criteria</u> <ul style="list-style-type: none">i. Emsamii. Equetroiii. Lambert-Eaton Myasthenic Syndrome (LEMS)iv. Oxandrinv. Ranexavi. Selective Serotonin Reuptake Inhibitors (SSRI) <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none">i. Botulinum Toxinii. Elagolixiii. Fintepla - <i>NEW</i>iv. Immunoglobulins (IVIG and SCIG) – <i>NEW</i>v. Narcolepsy Inhibitorsvi. Nuedexta – <i>NEW</i>vii. Palforzia - <i>NEW</i>viii. Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)ix. Transthyretin-Mediated Amyloidosis (ATTR)x. Uplizna - <i>NEW</i>xi. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors - <i>NEW</i>xii. Xcopri - <i>NEW</i>xiii. Zometa	Josh Moore

11:45 – 1:00

Preferred Drug List (PDL) Edits

Josh Moore

Existing Criteria

- i. ACE-Inhibitors/CCB Combinations
- ii. Anticoagulants
- iii. ARBs and ARBs/Diuretic Combinations
- iv. ARBs/CCB Combinations
- v. Direct Renin Inhibitors and Combinations
- vi. Dry Eye Disease
- vii. Homozygous Familial Hypercholesterolemia (HFHC)
- viii. Niacin Derivatives
- ix. PAH – Prostacyclins, Inhaled
- x. PAH – Prostacyclins, Oral
- xi. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors
- xii. Sympatholytics
- xiii. Triglyceride Lowering Agents

New Criteria or Revision of Existing Criteria

- i. ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations
- ii. ADHD – Amphetamines, Short-Acting
- iii. ADHD – Amphetamines, Long-Acting
- iv. ADHD – Methylphenidate, Short-Acting
- v. ADHD – Methylphenidate, Long-Acting
- vi. ADHD – Non-Stimulants
- vii. Anticonvulsants, Rescue Agents - *NEW*
- viii. Antiplatelets
- ix. Beta Blockers and Beta Blockers/Diuretic Combinations
- x. CCBs, Dihydropyridines
- xi. CCBs, Non-Dihydropyridines
- xii. PAH – Endothelin Receptor Antagonists (ETRA)s
- xiii. PAH – PDE5 Inhibitors and SGC Stimulators
- xiv. PAH – Prostacyclins, IV/SQ
- xv. Proton Pump Inhibitors
- xvi. Statins and Statin Combinations

1:00 – 1:15

LUNCH

1:15 – 1:30

Program Utilization Information – Conduent Update

Jennifer Colozza

- i. Call Center Statistics
- ii. CyberAccess User Statistics
- iii. New Drug Statistics
- iv. “Top 25” Drugs by Cost/Claims

1:30 – 1:50

Other Business

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

NEXT MEETING: January 20, 2021

Meeting via WebEx unless
otherwise specified